Statement: The differences between cohorts in the primary trial is once cohort recieves a 750mg Low-dose Omega-3 Fatty Acid and the other 500mg, in contrast the difference in the secondary trial is patient characteristics.
Primary_evidence: INTERVENTION 1:    Arm I (Low-dose Omega-3 Fatty Acid)   Patients receive low-dose omega-3 fatty acid supplementation PO BID and placebo PO BID for 6 weeks. Omega-3 Fatty Acid: Given PO   Placebo: Given PO   Questionnaire Administration: Ancillary studies   Laboratory Biomarker Analysis: Correlative studies INTERVENTION 2:    Arm II (High-dose Omega-3 Fatty Acid)   Patients receive high-dose omega-3 fatty acid supplementation PO BID for 6 weeks. Omega-3 Fatty Acid: Given PO   Questionnaire Administration: Ancillary studies   Laboratory Biomarker Analysis: Correlative studies
Secondary_evidence: INTERVENTION 1:    Cohort A   750mg lapatinib administered orally twice daily. Cohort A subjects had Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and one or two prior trastuzumab-containing regimens, in total, for treatment of breast cancer in adjuvant and/or metastatic settings INTERVENTION 2:    Cohort B   750mg lapatinib administered orally twice daily. Cohort B subjects had ECOG performance status 2 and/or more than 2 prior trastuzumab-containing regimens for treatment of breast cancer in the adjuvant and/or metastatic settings.